Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2009

01-07-2009 | Erratum

Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy

Authors: Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris, Nikolaos Kavantzas, Petros Kopterides, Thomas Papathomas, George Agrogiannis, Haralambos Zorzos, Vassiliki Kyriakou, Efstratios Patsouris

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2009

Login to get access

Excerpt

Unfortunately, two author names were published incorrect in the online version of the article. Correct names are given in the bold version. Instead of Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris, Nikolaos Kavantzas, Petros Kopterides, Thomas Papathomas, George Arapogiannis, Haralambos Zorzos, Vassiliki Kyriakou, Efstathios Patsouris it should read as Nicolas Tsavaris, Andreas Lazaris, Christos Kosmas, Panagiotis Gouveris, Nikolaos Kavantzas, Petros Kopterides, Thomas Papathomas, George Agrogiannis, Haralambos Zorzos, Vassiliki Kyriakou, Efstratios Patsouris. …
Metadata
Title
Topoisomerase I and IIα protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy
Authors
Nicolas Tsavaris
Andreas Lazaris
Christos Kosmas
Panagiotis Gouveris
Nikolaos Kavantzas
Petros Kopterides
Thomas Papathomas
George Agrogiannis
Haralambos Zorzos
Vassiliki Kyriakou
Efstratios Patsouris
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-0988-7

Other articles of this Issue 2/2009

Cancer Chemotherapy and Pharmacology 2/2009 Go to the issue

Original Article

Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

Short Communication

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

Original Article

Stable XIAP knockdown clones of HCT116 colon cancer cells are more sensitive to TRAIL, taxanes and irradiation in vitro

Original Article

Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells

Original Article

Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine

Original Article

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits